Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NIC24-02 (nicotine)
- Development stage
- Phase 1
- Lead developer
- Niconovum
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NIC24-02 is a nicotine-containing mouth spray formulation developed by Niconovum AB, a subsidiary of British American Tobacco, for the treatment of nicotine dependence. As a form of nicotine replacement therapy (NRT), it is designed to deliver nicotine rapidly through the oral mucosa to the systemic circulation, thereby mimicking the rapid nicotine uptake seen with cigarette smoking and providing quick relief from withdrawal symptoms and cravings. The pharmacological action is mediated through the activation of nicotinic acetylcholine receptors (nAChRs) in the brain and peripheral nervous system. Clinical development has focused on optimizing the pharmacokinetic profile of the spray to improve its efficacy in smoking cessation programs.
- Brand names
- Zonnic
02
Targets
Muscle-type nicotinic acetylcholine receptorα4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)CHRNA7 (α7 nicotinic receptor)
Beyond the preview
Go deeper on NIC24-02 (nicotine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NIC24-02 (nicotine).